全文获取类型
收费全文 | 37390篇 |
免费 | 2292篇 |
国内免费 | 656篇 |
专业分类
耳鼻咽喉 | 178篇 |
儿科学 | 472篇 |
妇产科学 | 456篇 |
基础医学 | 1842篇 |
口腔科学 | 191篇 |
临床医学 | 3556篇 |
内科学 | 3663篇 |
皮肤病学 | 512篇 |
神经病学 | 1361篇 |
特种医学 | 523篇 |
外国民族医学 | 1篇 |
外科学 | 1827篇 |
综合类 | 4570篇 |
一般理论 | 1篇 |
预防医学 | 4840篇 |
眼科学 | 267篇 |
药学 | 12558篇 |
20篇 | |
中国医学 | 1057篇 |
肿瘤学 | 2443篇 |
出版年
2023年 | 425篇 |
2022年 | 932篇 |
2021年 | 1154篇 |
2020年 | 1043篇 |
2019年 | 950篇 |
2018年 | 987篇 |
2017年 | 1014篇 |
2016年 | 1052篇 |
2015年 | 1205篇 |
2014年 | 2699篇 |
2013年 | 3195篇 |
2012年 | 2658篇 |
2011年 | 2976篇 |
2010年 | 2200篇 |
2009年 | 2077篇 |
2008年 | 2110篇 |
2007年 | 1960篇 |
2006年 | 1650篇 |
2005年 | 1366篇 |
2004年 | 1090篇 |
2003年 | 965篇 |
2002年 | 712篇 |
2001年 | 651篇 |
2000年 | 540篇 |
1999年 | 524篇 |
1998年 | 376篇 |
1997年 | 350篇 |
1996年 | 286篇 |
1995年 | 303篇 |
1994年 | 301篇 |
1993年 | 200篇 |
1992年 | 213篇 |
1991年 | 151篇 |
1990年 | 146篇 |
1989年 | 124篇 |
1988年 | 136篇 |
1987年 | 130篇 |
1986年 | 147篇 |
1985年 | 164篇 |
1984年 | 190篇 |
1983年 | 90篇 |
1982年 | 114篇 |
1981年 | 88篇 |
1980年 | 93篇 |
1979年 | 72篇 |
1978年 | 81篇 |
1977年 | 77篇 |
1976年 | 89篇 |
1975年 | 79篇 |
1974年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
The incidence of spontaneous pregnancy/infant losses is highly variable in long-tailed macaques (cynomolgus monkey), making it potentially difficult to ascertain test item-related effects in developmental toxicity studies. Therefore, pregnancy normograms had been developed by Jarvis et al. [1] to aid in the distinction of normal (e.g. test facility background) versus non-normal pregnancy outcomes. These normograms were mostly derived from embryo-fetal development studies and from PPND studies with a postnatal phase limited to seven days. However, the enhanced pre- and postnatal developmental (ePPND) study paradigm has essentially replaced these former study types. This work aims at providing enhanced normograms (e-normograms) in the context of regulatory ePPND studies. Survival functions for the prenatal phase (286 control pregnancies) and the postnatal phase (222 live infants) were estimated using the Kaplan-Meier estimator. Normograms were generated from survival curves and pseudo-study simulations. Data were available from two test facilities with comparable EU-compliant animal husbandry. Pregnancy duration/outcome as well as survival functions did not differ significantly between test facilities indicating that this husbandry system yields comparable developmental observations across different test facilities, at least in this NHP species. These novel e-normograms were developed for pregnant long-tailed macaques and provide an extended postnatal period up to three months, a new concept of separate normograms for the prenatal and the postnatal period, specific information on the perinatal phase events, a prediction of expected number of live infants for group size management, and the option to evaluate effects on pregnancy duration through distinction of live births and infant losses. 相似文献
92.
【摘要】 目的 评价度普利尤单抗治疗特应性皮炎(AD)的有效性和安全性。方法 采用回顾性研究方法,纳入2020年6月1日至2021年9月1日在北京大学第一医院皮肤科门诊外用药物控制不佳、规范使用度普利尤单抗注射治疗满16周的AD患者。收集患者基本信息以及治疗开始前、治疗第2、4、8、12、16周研究者整体评估(IGA)评分、湿疹面积及严重程度指数(EASI)评分、瘙痒数字评价量表(NRS)评分、皮肤病生活质量指数(DLQI)评分以及源自患者的湿疹评价(POEM)评分。记录治疗过程中出现的不良反应。采用Wilcoxon秩和检验对全部患者结束随访时各项评分和治疗前进行比较。结果 共纳入57例AD患者,均完成16周的注射药物治疗和随访观察。第16周时 ,患者自身IGA评分由基线4.0(4.0,5.0)分降至1.0(1.0,1.0)分(Z = 6.65,P < 0.001),EASI评分由30.0(17.2,36.0)分降至4.0(1.6,7.3)分(Z = 6.57,P < 0.001),瘙痒NRS评分由9.0(7.0,10.0)分降至1.0(0.0,1.0)分(Z = 6.59,P < 0.001),DLQI评分由15.0(11.5,20.5)分降至3.0(1.0,4.0)分(Z = 6.57,P < 0.001),POEM评分由19.0(15.5,23.0)分降至4.0(2.0,4.0)分(Z = 6.57,P < 0.001),差异均有统计学意义。5种评分16周内均呈持续下降趋势。仅2例患者出现结膜炎,无明显严重不良反应。结论 度普利尤单抗治疗AD疗效明显,且具有较好的安全性。 相似文献
93.
94.
目的分析真菌性血流感染的病原菌分布以及耐药特征,为真菌血流感染的早期合理用药提供理论依据。
方法回顾性分析武汉大学人民医院2016年1月至2018年12月收治的真菌性血流感染者的菌群、科室分布以及耐药性。
结果入组192例真菌血流感染者的血培养样本中共分离192株真菌,其中白色念珠菌检出率为31.77%(61/192),其次热带念珠菌检出率为18.75%(36/192);重症医学科检出率最高为33.85%(65/192)。所有菌株均对两性霉素B敏感,对其他抗菌药物耐药率分别为5-氟胞嘧啶4.49%(9/192)、伊曲康唑5.73%(11/192)、氟康唑10.94%(21/192)和伏立康唑11.46%(22/192);除两性霉素B外,2016至2018年真菌对其他抗菌药物的耐药率均逐年上升,其中2018年所分离192株光滑念珠菌对伊曲康唑耐药菌率达46.7%。
结论真菌血流感染病原菌以念珠菌属为主,对目前抗真菌药物具有较高敏感性,但耐药率逐年上升,加强监测血培养病原菌变化及耐药趋势对指导临床用药至关重要。 相似文献
95.
目的:通过对英国癌症药物基金(Cancer Drugs Fund, CDF)的形成背景、运行机制及改革中优化管理策略进行批判借鉴研究,为中国创新药准入及管理政策的制定提供参考。方法:文献梳理、政策分析。结果:CDF在解决癌症患者创新药的可及性、可负担性方面具有积极意义,但同时存在较大争议。CDF通过不断改革完善、优化基金管理办法,在药品准入和退出机制、审批流程规范化、预算管理风险分摊协议等方面做出优化调整。结论和建议:CDF在癌症创新药快速准入方面的经验及教训值得我国批判借鉴。中国的创新药支付政策方面,建议可成立多元化筹资的癌症药物基金,建立药物准入及退出机制,关注真实世界数据在支付决策中的作用,探索合理超支分担科学管理的预算协议。 相似文献
96.
《Clinical microbiology and infection》2020,26(3):384.e1-384.e4
ObjectivesChagas disease (CD) treatment is limited to two therapeutic options: benznidazole (generally the first option in Spain) and nifurtimox. Both drugs present high rates of adverse reactions and treatment discontinuation and there is no consensus regarding the most effective administration schedule for benznidazole or how to prevent and manage treatment toxicity. We aim to compare the tolerability and treatment discontinuation rate between two different treatment schemes with benznidazole.MethodsThis was a prospective observational study of adult patients with CD, enrolled from January 2014 to March 2018 in two referral centres in Madrid (Spain). Participants were treated either with benznidazole 5 mg/kg/day (full dose) over 60 days (benznidazole standard dose scheme (BSD)), or with an escalating dose lasting 5 days up to a maximum of 300 mg/day (benznidazole increasing dose scheme (BID)).Results471 patients were analysed: 201 in the BSD group and 270 in the BID group. There were no significant differences regarding age (40.4 (SD 8.7) vs 41 (SD 8.2) years), sex (74.1% (149/201) vs 68.5% (185/270) women), weight (69.4 (SD 12.8) vs 68.9 (SD 11) kg) or nationality (97.5% (196/201) vs 96.7% (261/270) Bolivians) between groups. There were also no differences in adverse reactions rate (55.2% (111/201) vs 55.6% (150/270)), number of adverse reactions per patient, adverse reactions type (except for arthralgias and myalgias which occurred more frequently in the BID group (0% (0/111) BSD vs 8% (12/150) BID; p 0.002)) and degree and time to first adverse reactions. There was significantly more treatment discontinuation (49.8% (100/201) vs 33.0% (89/270); p <0.001) in the BSD group, but not during the first 30 days of treatment (32.3% (65/201) vs 25.6% (69/270); p 0.08).ConclusionThe use of increasing doses of benznidazole for 5 days and a maximum dose of 300 mg, does not significantly improve drug tolerability. However, while the treatment discontinuation rates were similar during the first 30 days of treatment, it may improve the treatment completion rate at 60 days. 相似文献
97.
《Anais brasileiros de dermatologia》2020,95(1):63-66
Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic circulation of pro-inflammatory cytokines. This report describes a case of development of pityriasis rubra pilaris, a rare erythematous-papulosquamous dermatosis, in a woman aged 60 years during treatment with imiquimod 5% cream for actinic keratosis. It evolved with erythrodermic conditions and palmoplantar keratoderma, presenting progressive clinical resolution after the introduction of methotrexate. The authors emphasize the importance of recognizing possible systemic reactions associated with the topical use of imiquimod. 相似文献
98.
《Anais brasileiros de dermatologia》2020,95(1):1-14
These are cutaneous diseases caused by insects, worms, protozoa, or coelenterates which may or may not have a parasitic life. In this review the main ethological agents, clinical aspects, laboratory exams, and treatments of these dermatological diseases will be studied. 相似文献
99.
《Anais brasileiros de dermatologia》2020,95(5):631-637
Chemotherapy-induced alopecia causes an important impact on cancer patients and its risk of persistence is currently a considerable issue in cancer survivors. Of the various interventions proposed for the prevention of chemotherapy-induced alopecia, scalp cooling has emerged as an effective and safe strategy. This paper aims to provide an overview on scalp cooling and chemotherapy-induced alopecia prevention. 相似文献
100.
恶性黑素瘤免疫检查点抑制疗法研究进展 总被引:1,自引:0,他引:1
【摘要】 免疫检查点抑制剂在过去几年中已成为许多恶性黑素瘤患者的重要治疗选择,其旨在恢复并促进效应T细胞特异性识别和杀伤肿瘤细胞的功能,系统性增强全身的抗肿瘤免疫反应,对于手术切除后具有高复发风险或处于疾病晚期(不可切除或存在转移)的患者都是较好的治疗选择。目前免疫检查点抑制的主要目标是程序性死亡受体 1与细胞毒性T淋巴细胞相关抗原4,它们分别是中枢和外周免疫耐受的两个关键受体。本文主要讨论不同免疫检查点抑制剂的临床效应、可能存在的药物反应性预测标志物与相关不良反应。 相似文献